← Back to Clinical Trials
Recruiting NCT05700058

NCT05700058 Assessing the Dose-response of Muscle Protein Synthesis to "Super-whey" in Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05700058
Status Recruiting
Phase
Sponsor University of Nottingham
Condition Sarcopenia
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2023-01-31
Primary Completion 2026-09

Eligibility & Interventions

Sex Male only
Min Age 65 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Dietary protein supplement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2023-01-31 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Skeletal muscle accounts for approximately 45-55% of total body mass in healthy adults and plays a pivotal role in whole-body metabolic health, locomotion and physical independence. Undesirable loss of skeletal muscle mass (atrophy) is, however, a common feature of many diseases and scenarios including ageing, bed rest/immobilisation, cancer and physical inactivity. Despite the exact mechanisms causing muscle atrophy being not yet fully understood, "anabolic resistance" (reduced muscle building in response to protein feeding and exercise) is thought to be key, especially for age-related skeletal muscle losses (known as sarcopenia). As such, the search for optimal strategies (e.g., exercise and/ or nutritional interventions) to combat this anabolic blunting remains a hot-topic in scientific research. Leucine, an essential and branched chain amino acid (EAA/BCAA), is thought to be the most potent AA for stimulating muscle protein synthesis (MPS; the muscle building process). Although, as a stand-alone supplement, leucine is unlikely to provoke a robust and prolonged state of MPS, low doses of leucine-enriched mixed-EAAs can elicit similar increases in MPS as compared to a large dose of whey protein. As reduced appetite and increased satiety (feeling fuller) are common with advancing age, supplementation of a low-dose protein (i.e., leucine-enriched) that can adequately stimulate MPS may contribute to muscle health maintenance in older adults and reduce satiation following a meal. This study aims to examine which of three doses of a novel leucine-enriched whey protein ("super-whey") best stimulates muscle building in older adults

Eligibility Criteria

Inclusion Criteria: * Participant is in the desired age-ranges (young adults: 18-35 years; older adults: 65+ years). * Participant is willing and able to give informed consent for participation in the study. * Participant is physically able to perform resistance exercise Exclusion Criteria: * A BMI \<18 or \>35 kg/m2 * Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent (6 mo) stroke * Any metabolic disease * Clotting dysfunction * A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy) * Lactose intolerance * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Frequently Asked Questions

Who can join the NCT05700058 clinical trial?

This trial is open to male participants only, aged 65 Years or older, up to 85 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05700058 currently recruiting?

Yes, NCT05700058 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Nottingham to inquire about joining.

Where is the NCT05700058 trial being conducted?

This trial is being conducted at Derby, United Kingdom.

Who is sponsoring the NCT05700058 clinical trial?

NCT05700058 is sponsored by University of Nottingham. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology